Wegovy 1mg FlexTouch

Administered once weekly via subcutaneous injection using the pre-filled FlexTouch pen, Wegovy facilitates sustained plasma concentrations of semaglutide, optimizing therapeutic efficacy. Clinical trials have demonstrated significant weight reduction and improvement in metabolic parameters with Wegovy compared to placebo when combined with lifestyle interventions including diet and exercise.

Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation, which tend to diminish over time. Caution is advised in patients with a history of pancreatitis, medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2. Wegovy should be used under medical supervision with appropriate monitoring to ensure safety and effectiveness in weight management.